Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Telix Pharmaceuticals Limited
  6. News
  7. Summary
    TLX   AU000000TLX2

TELIX PHARMACEUTICALS LIMITED

(TLX)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Telix Pharmaceuticals : Recruiting Patients for Phase 3 Study of Renal Cancer Imaging Drug

07/20/2021 | 02:29am EDT


ę MT Newswires 2021
All news about TELIX PHARMACEUTICALS LIMITED
09/23TELIX PHARMACEUTICALS : US FDA Extends Review Process for Telix Pharmaceuticals' Prostate ..
MT
09/22Telix Pharmaceuticals Limited Announces FDA Extends New Drug Application Review Period ..
CI
09/20Second Industry Body Updates Guidance for Use of PSMA PET Imaging
GL
09/14Telix Pharmaceuticals Limited Announces Supplying Illuccix« (Investigational Kit for th..
CI
09/14TELIX PHARMACEUTICALS : Secures US FDA Approval for Phase 2 Kidney Cancer Study
MT
09/13NCCN Guidelines Updated to Include PSMA-PET Imaging
GL
09/13FDA Approves Phase II Kidney Cancer Therapy Study
GL
09/13Telix Pharmaceuticals Limited Announces That the United States Food and Drug Administra..
CI
09/12TELIX PHARMACEUTICALS : Secures Italian Distributor for Prostate Cancer Imaging Drug
MT
09/12Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
GL
More news
Financials
Sales 2021 12,4 M 8,99 M 8,99 M
Net income 2021 -54,6 M -39,6 M -39,6 M
Net cash 2021 38,5 M 28,0 M 28,0 M
P/E ratio 2021 -32,0x
Yield 2021 -
Capitalization 1 704 M 1 235 M 1 237 M
EV / Sales 2021 134x
EV / Sales 2022 22,6x
Nbr of Employees -
Free-Float 62,0%
Chart TELIX PHARMACEUTICALS LIMITED
Duration : Period :
Telix Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TELIX PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 6,05 AUD
Average target price 6,94 AUD
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Christian P. Behrenbruch Group CEO, MD & Executive Director
Douglas Cubbin Chief Financial Officer
Harry Kevin McCann Independent Non-Executive Chairman
Colin Hayward Chief Medical Officer
Michael Wheatcroft Chief Scientist
Sector and Competitors
1st jan.Capi. (M$)
TELIX PHARMACEUTICALS LIMITED60.05%1 235
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353